Eledon Pharmaceuticals, Inc.（ELDN）今日宣布，其研发药物Tegoprubart已获得孤儿药资格认定，适应症为预防肝移植中的同种异体移植物排斥反应。
孤儿药资格认定将为Tegoprubart的后续开发提供政策支持，包括临床试验税收优惠、上市申请费用减免以及获批后的市场独占期等优势。该认定进一步凸显了Tegoprubart在解决肝移植领域未满足医疗需求方面的潜力。
Eledon Pharmaceuticals, Inc.（ELDN）今日宣布，其研发药物Tegoprubart已获得孤儿药资格认定，适应症为预防肝移植中的同种异体移植物排斥反应。
孤儿药资格认定将为Tegoprubart的后续开发提供政策支持，包括临床试验税收优惠、上市申请费用减免以及获批后的市场独占期等优势。该认定进一步凸显了Tegoprubart在解决肝移植领域未满足医疗需求方面的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.